LTR Pharma has today announced that it has successfully completed a A$10.5 million Share Placement to sophisticated and new institutional investors to expedite the commercialisation of SPONTAN®.

Funds will be deployed to advance SPONTAN’s regulatory pathways, expand R&D pipeline, and bolster sales and marketing efforts.

LTR Pharma Chairman, Lee Rodne, commented:

“This capital injection will accelerate our regulatory engagements, strengthen our market entrance strategy through additional headcount, develop online product channels, and support partnering and licensing discussions. We’ll initially leverage Australian early access schemes, whilst exploring potential partnerships with major pharmaceutical companies globally. We’re excited about the Company’s future and appreciate our shareholders’ continued support.”

Click here to view ASX release